{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:58:42Z","timestamp":1791500322853,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.07.007","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"295-302","source":"Crossref","is-referenced-by-count":124,"title":["Epidemiology of chronic myeloid leukaemia (CML)"],"prefix":"10.1016","volume":"22","author":[{"given":"Maren","family":"Rohrbacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2009.07.007_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.07.007_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrc1948","article-title":"The evolution of the population-based cancer registry","volume":"6","author":"Parkin","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beha.2009.07.007_bib3","author":"Swedish Cancer Registry"},{"key":"10.1016\/j.beha.2009.07.007_bib5","series-title":"SEER cancer statistics review","author":"Ries","year":"1975"},{"issue":"Suppl. 5","key":"10.1016\/j.beha.2009.07.007_bib6","doi-asserted-by":"crossref","first-page":"v41","DOI":"10.1093\/annonc\/mdg753","article-title":"European health systems and cancer care","volume":"14","author":"Micheli","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2009.07.007_bib7","first-page":"1400","article-title":"The incidence and outcome of myeloid malignancies in 2112 adult patients in southeast-England","volume":"91","author":"Phekoo","year":"2006","journal-title":"Haematologica- Hematol J"},{"key":"10.1016\/j.beha.2009.07.007_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/003693300404900305","article-title":"The Scotland leukaemia registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000","volume":"49","author":"Harrison","year":"2004","journal-title":"Scott Med J"},{"key":"10.1016\/j.beha.2009.07.007_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1099-1069(199711)15:4<173::AID-HON610>3.0.CO;2-K","article-title":"Age and sex distributions of hematological malignancies in the U.K","volume":"15","author":"McNally","year":"1997","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2009.07.007_bib10","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","article-title":"Clinical trials underestimate age of chronic myeloid leukemia (CML) Patients. Incidence and median age of Ph\/BCR-ABL positive CML and other chronic myeloproliferative disorders in a representative area in Germany","volume":"23","author":"Rohrbacher","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.07.007_bib11","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2964.2964","article-title":"Incidence, co-morbidity and treatment survey of chronic myeloid leukemia in Germany","volume":"110","author":"Hasford","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.7088","article-title":"Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib","volume":"26","author":"Corm","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.07.007_bib13","author":"Ahmad"},{"key":"10.1016\/j.beha.2009.07.007_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1034\/j.1600-0609.2000.065004267.x","article-title":"Incidence of chronic myeloproliferative disorders in the city of G\u00f6teborg, Sweden 1983\u20131992","volume":"65","author":"Ridell","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2009.07.007_bib15","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1182\/blood.V87.12.5384.bloodjournal87125384","article-title":"Interferon-a and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-a","volume":"88","author":"Hasford","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib16","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.07.007_bib17","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/annonc\/mdf127","article-title":"Cancer prevalence in European registry areas","volume":"13","author":"Micheli","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2009.07.007_bib18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/pds.1046","article-title":"Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients","volume":"14","author":"Tardieu","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.beha.2009.07.007_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/eurpub\/ckn022","article-title":"Patient survival for all cancers combined as indicator of cancer control in Europe","volume":"18","author":"Verdecchia","year":"2008","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.beha.2009.07.007_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/eurpub\/13.suppl_1.116","article-title":"Cancer control in Europe: a proposed set of European cancer health indicators","volume":"13","author":"Micheli","year":"2003","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.beha.2009.07.007_bib21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib22","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/cncr.22523","article-title":"Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.07.007_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1951.1951","article-title":"Imatinib resistance and\/or intolerance in clinical practice in Europe: the \u201cUnmet needs in CML and Ph+ALL\u201d (UNIC) study","volume":"110","author":"Michallet","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1959.1959","article-title":"Real-life rates of disease monitoring in clinical practice in Europe: the \u201cUnmet needs in CML and Ph+ALL\u201d (UNIC) Study","volume":"110","author":"Morra","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib25","unstructured":"\u201cIt`s best to test\u201d survey: an assessment of CML monitoring across Europe. This survey was conducted between November 2007 and February 2008 by the independent market research agency TNS and funded by Bristol-Myers Squibb. Bristol-Myers Squibb, 2008."},{"key":"10.1016\/j.beha.2009.07.007_bib26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.07.007_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","article-title":"Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML working party","volume":"92","author":"Rosti","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.07.007_bib28","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib29","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A randomized study of interferon-alpha versus interferon-alpha and low- dose arabinosyl cytosine in chronic myeloid leukemia","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib30","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib31","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2009.07.007_bib32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alpha2b (IFN) combined with cytarabine versus interferon alone in chronic myelogenous leukemia","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.07.007_bib33","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beha.2009.07.007_bib34","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.leu.2403006","article-title":"Randomized comparison of Interferon-a and Hydroxyurea with Hydroxyurea monotherapy in Chronic Myeloid Leukemia (CML-Study II): prolongation of survival by the combination of Interferon-a and Hydroxyurea","volume":"17","author":"Hehlmann","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.07.007_bib35","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib36","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V86.3.906.906","article-title":"A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase","volume":"86","author":"Ohnishi","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib37","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia","volume":"330","author":"The Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.07.007_bib38","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1182\/blood.V91.8.2713.2713_2713_2721","article-title":"Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-a2b for chronic myeloid leukemia","volume":"91","author":"The Benelux CML Study Group","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib39","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1182\/blood-2003-10-3605","article-title":"Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups","volume":"103","author":"Kluin-Nelemans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib40","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon alpha-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.07.007_bib41","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/cncr.11316","article-title":"Trends in leukemia incidence and survival in the United States (1973\u20131998)","volume":"97","author":"Xie","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.07.007_bib42","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.leu.2403756","article-title":"Gender aspects in chronic myeloid leukemia: long-term results from randomized studies","volume":"19","author":"Berger","year":"2005","journal-title":"Leukemia"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T00:59:11Z","timestamp":1590281951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1521692609000401"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.07.007","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}